Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Non Operating Income (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Non Operating Income for 12 consecutive years, with $4.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income rose 192.44% to $4.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.4 million, a 29.06% increase, with the full-year FY2024 number at $4.9 million, down 46.46% from a year prior.
  • Non Operating Income was $4.1 million for Q3 2025 at Theravance Biopharma, up from $1.5 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $4.1 million in Q3 2025 to a low of -$375000.0 in Q1 2022.
  • A 5-year average of $1.7 million and a median of $1.4 million in 2024 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: tumbled 116.03% in 2021, then soared 894.4% in 2023.
  • Theravance Biopharma's Non Operating Income stood at $1.2 million in 2021, then surged by 217.85% to $3.7 million in 2022, then tumbled by 52.02% to $1.8 million in 2023, then tumbled by 49.38% to $904000.0 in 2024, then skyrocketed by 357.74% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Non Operating Income are $4.1 million (Q3 2025), $1.5 million (Q2 2025), and $939000.0 (Q1 2025).